Agenus' BOT+BAL Shows 48% Three-Year Survival in Recurrent Ovarian Cancer
AGEN has more than doubled off its 52-week low of $2.71 on light trading volume (0.3× avg).
Summary
Agenus presented three-year follow-up data from its Phase 1b C-800-01 trial in recurrent ovarian cancer at IGCS 2026. The combination of botensilimab and balstilimab achieved an estimated 48% three-year overall survival in 35 efficacy-evaluable patients, with the survival curve plateauing from two to three years. Notably, 25% of all treated patients (11 of 44) were alive and off all therapy at last follow-up. The population was heavily pretreated (median four prior lines, 66% with ≥4 lines, 77% prior bevacizumab, 57% prior PARP inhibitor) and nearly three-quarters had platinum-resistant or refractory disease. Subgroup analyses showed consistent survival benefit across platinum sensitivity status and prior treatment lines, with a 61% three-year survival in patients who progressed on PARP inhibitors. These results add to a pattern of durable survival seen with BOT+BAL in other difficult-to-treat cancers, supporting the company's rationale for moving the combination earlier in treatment. The data reinforce the potential of BOT+BAL in a setting where conventional checkpoint immunotherapy has shown limited benefit, though the small sample size and single-arm design warrant caution. This follows the company's recent strategic pivot to the pivotal Phase 3 ROBBIN trial and its $85M private placement to fund development.
At the time of this announcement, AGEN was trading at $8.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $377.6M. The 52-week trading range was $2.71 to $10.31. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.